Peer-reviewed publications

  • Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis
    Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L
    Acta Neuropathol 2016 Oct 4; [Epub ahead of print]
  • Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
    Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA
    Sci Transl Med 2016 Sep 21;8(357):357ra123
  • Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Jul 21; [Epub ahead of print]
  • Longitudinal body composition changes in diffuse large B-cell lymphoma survivors: a retrospective cohort study of United States veterans
    Xiao DY, Luo S, O’Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR
    J Natl Cancer Inst 2016 Jul 5;108(11); [Epub ahead of print]
  • Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • Transcriptional and post-transcriptional regulation of NK cell development and function
    Leong JW, Wagner JA, Ireland AR, Fehniger TA
    Clin Immunol 2016 Mar 3; [Epub ahead of print]
  • The IL-15-based ALT-803 complex enhances FcgRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas
    Rosario M, Liu B, Kong L, Collins L, Schneider SE, Chen X, Han KP, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell B, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms D, Cashen A, Bartlett NL, Wong HC, Fehniger TA
    Clin Cancer Res 2015 Sep 30; [Epub ahead of print]
  • Improving natural killer cell cancer immunotherapy
    Berrien-Elliott MM, Romee R, Fehniger TA
    Curr Opin Organ Transplant 2015 Sep 25; [Epub ahead of print]
  • MicroRNA-15/16 antagonizes Myb to control NK cell maturation
    Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA
    J Immunol 2015 Sep 15;195(6):2806-17
  • Human cytokine-induced memory-like natural killer cells
    Berrien-Elliott MM, Wagner JA, Fehniger TA
    J Innate Immun 2015 Apr 30; [Epub ahead of print]
  • Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • PTEN regulates natural killer cell trafficking in vivo
    Leong JW, Schneider SE, Sullivan RP, Parikh BA, Anthony BA, Singh A, Jewell BA, Schappe T, Wagner JA, Link DC, Yokoyama WM, Fehniger TA
    Proc Natl Acad Sci U S A 2015 Feb 17;112(7):E700-9
  • Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O’Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • MicroRNA management of NK-cell developmental and functional programs
    Leong JW, Sullivan RP, Fehniger TA
    Eur J Immunol 2014 Oct;44(10):2862-8
  • Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer
    Romee R, Leong JW, Fehniger TA
    Scientifica (Cairo) 2014;2014:205796
  • Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA. Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells.  Biol Blood Marrow Transplant 2014; 14: Epub Jan 2014
  • Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW 2nd, French AR, Fehniger TA. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways.  J Immunol 2013;191:5904 Epub Nov 2013
  • Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, Dipersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.             Biol Blood Marrow Transplant 2014;20:46
  • Sullivan RP, Leong JW, Fehniger TA
    MicroRNA regulation of natural killer cells.
    Front Immunol 2013;4:44
  • Leong JW, Sullivan RP, Fehniger TA Natural killer cell regulation by microRNAs in health and disease. J Biomed Biotechnol. 2012;2012:632329
  • Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G
    Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
    Blood 2013 Jan 3;121(1):159-69
  • Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA.  Cytokine activation induces human memory-like NK cells. Blood 2012 120(24):4751-60
  • Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J
    T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
    Biol Blood Marrow Transplant 2012 Jun;18(6):937-43
  • Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA
    MicroRNA-deficient NK cells exhibit decreased survival but enhanced function.
    J Immunol 2012 Apr 1;188(7):3019-30
  • Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
    Blood 2011 Nov 10;118(19):5119-25
  • Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.
    Blood 2011 Feb 10;117(6):1828-33
  • Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, Ley TJ, Mardis ER
    Next-generation sequencing identifies the natural killer cell microRNA transcriptome.
    Genome Res 2010 Nov;20(11):1590-604
  • Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, Chang LW, Nagarajan R, Fehniger TA, Goodfellow P, Magrini V, Wilson RK, Ding L, Ley TJ, Mardis ER, Link DC
    Complete characterization of the microRNAome in a patient with acute myeloid leukemia.
    Blood 2010 Dec 9;116(24):5316-5326
  • Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ
    Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice.
    Leukemia 2010 Sep;24(9):1662-4
  • White DW, Keppel CR, Schneider SE, Reese TA, Coder J, Payton JE, Ley TJ, Virgin HW, Fehniger TA
    Latent herpesvirus infection arms NK cells.
    Blood 2010 Jun 3;115(22):4377-83
  • Cai SF, Cao X, Hassan A, Fehniger TA, Ley TJ
    Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease.
    Blood 2010 Mar 4;115(9):1669-77
  • Cai SF, Fehniger TA, Cao X, Mayer JC, Brune JD, French AR, Ley TJ
    Differential expression of granzyme B and C in murine cytotoxic lymphocytes.
    J Immunol 2009 May 15;182(10):6287-97
  • Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
    Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
    Blood 2009 Jan 29;113(5):1002-5
  • Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ
    Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.
    Immunity 2007 Oct;27(4):635-46
  • French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM
    Chronic lymphocytosis of functionally immature natural killer cells.
    J Allergy Clin Immunol 2007 Oct;120(4):924-31
  • Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ
    Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs.
    Immunity 2007 Jun;26(6):798-811
  • Bredemeyer AJ, Carrigan PE, Fehniger TA, Smith DF, Ley TJ
    Hop cleavage and function in granzyme B-induced apoptosis.
    J Biol Chem 2006 Dec 1;281(48):37130-41
  • Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA
    CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.
    Blood 2003 Apr 15;101(8):3052-7
  • Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA
    Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
    Clin Cancer Res 2002 Sep;8(9):2812-9
  • Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA
    In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells.
    Blood 2002 Nov 15;100(10):3633-8
  • Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA
    Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.
    Blood 2002 Sep 15;100(6):1935-47
  • Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ
    Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system.
    Cytometry 2001 Dec 1;45(4):285-93
  • Cooper MA, Fehniger TA, Caligiuri MA
    The biology of human natural killer-cell subsets. [Review]
    Trends Immunol 2001 Nov;22(11):633-40
  • Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA
    Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.
    Blood 2001 May 15;97(10):3146-51
  • Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA
    Interleukin-1beta costimulates interferon-gamma production by human natural killer cells.
    Eur J Immunol 2001 Mar;31(3):792-801
  • Fehniger TA, Caligiuri MA
    Interleukin 15: biology and relevance to human disease. [Review]
    Blood 2001 Jan 1;97(1):14-32
  • Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA
    Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.
    J Exp Med 2001 Jan 15;193(2):219-31
  • Fehniger TA, Bluman EM, Porter MM, Mrozek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA
    Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.
    J Clin Invest 2000 Jul;106(1):117-24
  • Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA
    Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo.
    J Immunol 2000 Feb 15;164(4):1643-7
  • Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA
    Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
    J Immunol 1999 Apr 15;162(8):4511-20
  • Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA
    Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.
    Blood 1998 Nov 15;92(10):3647-57
  • Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O’Brien WA, Caligiuri MA
    Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.
    J Immunol 1998 Dec 1;161(11):6433-8
  • Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA
    Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
    Cancer Immunol Immunother 1998 Aug;46(6):318-26
  • Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS
    Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.
    J Immunol 1998 Jul 1;161(1):400-8
  • Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA
    Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.
    J Clin Invest 1998 Mar 15;101(6):1373-8
  • Fehniger TA, Carson WE, Mrozek E, Caligiuri MA
    Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.
    Blood 1997 Nov 1;90(9):3647-53
  • Carson WE, Fehniger TA, Caligiuri MA
    CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Eur J Immunol 1997 Feb;27(2):354-60
  • Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA
    A potential role for interleukin-15 in the regulation of human natural killer cell survival.
    J Clin Invest 1997 Mar 1;99(5):937-43

Invited Reviews and Book Chapters

  • Fehniger TA
    Chapter 31. Lymphoma.
    In: The Washington Manual, Hematology and Oncology Subspecialty Consult, 2nd Edition (Cashen AF, Wildes T, eds), Lippincott, Williams, and Wilkins, Philadelphia, PA, 2008
  • Fehniger TA, Welch JS, Pluard TJ
    Chapter 31. Hematologic malignancies: chronic leukemias.
    In: The Washington Manual of Oncology, 2nd Edition (Govindan R, ed), Lippincott, Williams, and Wilkins, Philadelphia, PA, 2007
  • Fehniger TA, Cooper MA, Caligiuri MA
    Chapter 12. Murine cytokine models and the genesis of cancer.
    In: Cytokines in the genesis and treatment of cancer (Caligiuri MA, Lotze MT, eds), Humana Press, Totowa, NJ, 2007